窩客幫-分身行銷廣告平台

MiMed Medical Introduces European Autologous Micrografting Technology (AMT®), Expanding Horizons in Musculoskeletal Research and Joint Care

Focusing on Joint Health: Exploring Emerging Perspectives on Tissue Repair

Joints are composed of cartilage, bones, ligaments, and other tissues that play an essential role in supporting mobility and daily physical activities. When joints are affected by external trauma, sports injuries, or prolonged mechanical stress, the resulting damage may be associated with restricted movement and discomfort.

As articular cartilage is avascular and has a relatively limited capacity for self-repair, exploring biological repair strategies based on autologous human tissue, beyond conventional symptom management, has become an important area of research in musculoskeletal medicine and regenerative medicine.

Introducing Internationally Patented Technology: Opening a New Chapter in Micro-Processing Autologous Tissues

MiMed Medical has long been committed to introducing advanced medical technologies from around the world, with a focus on scientific foundations and potential clinical relevance. Recently, the company officially introduced the Autologous Micrografting Technology (AMT®) system developed by an Italian manufacturer.

Using the patented Rigenera® mechanical processing device, the system enables the mechanical microprocessing of small autologous tissue samples under standardized aseptic conditions. The process is designed to preserve components of the tissue's native extracellular matrix and biological structure, providing a stable and efficient platform for sample preparation in research involving local tissue microenvironments and tissue regeneration.

Focusing on Clinical Indicators and Scientific Validation: Connecting Global Innovation with Local Needs

Autologous Micrografting Technology (AMT®) has been investigated internationally in research involving tissue microenvironments and the musculoskeletal system. Clinical investigations have employed assessment methods such as the Visual Analog Scale (VAS), joint function evaluations, and advanced magnetic resonance imaging (MRI) to examine outcomes related to joint mobility, functional stability, and structural changes.

These investigations contribute to the scientific understanding of the technology and its potential applications in musculoskeletal research.

This technology reflects an innovative approach to fully utilizing autologous biological resources and offers new perspectives for research into joint health management and future tissue repair strategies.

Looking ahead, MiMed Medical will continue to collaborate with healthcare institutions and research teams in Taiwan and internationally. Through professional exchanges, technical information integration, and standardized educational training, the company aims to support the scientific development of autologous micrografting technology in the musculoskeletal field and contribute to the continued advancement of medical innovation in Taiwan.